---
schema_version: "secwatch.filing_event.v1"
accession: "0001087294-26-000076"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2026-11-10T22:06:04+00:00"
generated_at: "2026-11-10T22:08:08.444644+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cumberland posts Q3 net income of $77.8M on Apotex divestiture gain; plans ifetroban NDA in DMD

## Summary
- Net income of $77.8M in Q3 2026, driven by the gain on divestiture of commercial brands to Apotex Health, whose $100M strategic transaction closed July 1, 2026.
- Cash and equivalents of $80.6M at September 30, 2026; total assets ~$114M, liabilities $42M and shareholders' equity $73M.
- Will submit an NDA for ifetroban in DMD cardiomyopathy after a fall pre-NDA meeting; FDA granted a rolling review and conditionally accepted DYSCORBAN as the name.
- Phase 2 FIGHT DMD showed a 5.4 percentage point LVEF improvement (p=0.002) in the high-dose group; safety database exceeds 1,400 subjects across ~30 studies.
- Phase 2a ASSIST-SSc top-line: ifetroban generally well tolerated, no drug-related serious AEs over 12 months; Cumberland to submit the study report to FDA, SSc decision pending.

## SEC filing metadata
- accession: 0001087294-26-000076
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2026-11-10T22:06:04+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000076/0001087294-26-000076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000076/cpix-20261110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001087294-26-000076
- JSON: https://secwatch.observer/filing/0001087294-26-000076.json
- Plain text: https://secwatch.observer/filing/0001087294-26-000076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.